Pharmaceutical compounds

A technology of compounds and drugs, applied in the field of medicinal compounds, can solve problems affecting product performance, efficacy and tolerance reduction, etc.

Inactive Publication Date: 2007-03-07
NICOX SA
View PDF1 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In addition, in the case of bile acids, oxidative stress significantly affects the performance of the product: both chenodeoxycholic acid and ursodeoxycholic acid are significantly less effective and tolerable

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical compounds
  • Pharmaceutical compounds
  • Pharmaceutical compounds

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0262] Preparation of 4'-acetylaminophenyl 4-nitroxy (nitroxy) butyrate

[0263]

[0264] The drug is acetaminophen of the formula

[0265]

[0266] The precursor compound of B is 4-hydroxybutyric acid.

[0267] a) Preparation of 4'-acetylaminophenyl 4-bromobutyrate

[0268] To a solution of 4-bromobutyric acid (4.6g, 27.6mmol) in chloroform (45ml) and N,N-dimethylformamide (20ml) was added paracetamol (4.17g, 27.6mmol), N , N'-dicyclohexylcarbodiimide (8.42 g, 40.8 mmol) and 4-dimethylaminopyridine (0.15 g, 1.25 mmol). The reaction mixture was maintained under stirring at room temperature for 72 hours, filtered and evaporated under vacuum. The crude reaction was treated with ethyl acetate, washed with brine then water. The organic phase was dried with sodium sulfate and evaporated under vacuum. The residue was purified by silica gel chromatography, eluting with n-hexane / ethyl acetate 4 / 6 (v / v ratio). 5.33 g of product were obtained as a white solid. M.p. = 108°C-...

Embodiment 2

[0275] Preparation of 4-Hydroxy-3-(4-nitroxybutyryloxymethyl)-α-[(tetrabutylamino)methyl]benzyl alcohol

[0276]

[0277] The prodrug is albuterol of the formula

[0278]

[0279] The precursor compound of B is 4-hydroxybutyric acid.

[0280] According to the method described in Example 1, compound (E-2) was synthesized. Yield: 21%.

[0281] Elemental analysis: CHN

[0282] Calculated value 55.13% 7.07% 7.56%

[0283] Measured value 55.10% 7.09% 7.57%

Embodiment 3

[0285] Preparation of 4-(nitroxyl)butanoic acid 4-[(2-amino-3,5-dibromophenyl)methylamino]trans-cyclohexyl ester

[0286]

[0287] Ambroxol

[0288]

[0289] The precursor compound of A is 4-hydroxybutyric acid.

[0290] a) Preparation of 4-[(2-tert-butoxycarbonylamino-3,5-dibromophenyl)methylamino]trans cyclohexanol

[0291] To a solution of ambroxol (5g, 13.22mmol) in dioxane (35ml) and water (50ml) was added triethylamine (3.31ml, 23.7mmol) and di-tert-butyl dicarbonate (3.46g, 15.86mmol) . The reaction mixture was left under stirring at room temperature for 24 hours, then concentrated under reduced pressure. The residue was treated by portionwise addition of 1% HCl solution until pH 7, then the solution was extracted with ethyl acetate. The organic phase anhydrated with sodium sulfate was evaporated under vacuum. This gave 4-[(2-tert-butoxycarbonylamino-3,5-dibromophenyl)methylamino]transcyclohexanol which was used in the next step without further purification. ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Compounds or their salts of general formula (I): A-B-N(O)2 wherein: A is a drug radical selected from ferulic acid and sulindac; B= -O-R1B-X-R2B-O- wherein R1B and R2B, equal to or different from each other, are linear or branched C1-C6 alkylenes, and X = a free valence or O, S, NR1C, R1C is H or a linear or branched alkyl, having from 1 to 6 carbon atoms.

Description

[0001] This application is a divisional application of the following applications: filing date: July 27, 2000; application number: 00814049.9 (PCT / EP00 / 07225); invention name: "pharmaceutical compound". field of invention [0002] The present invention relates to new medicaments for systemic and non-systemic use, and to compositions thereof for moderate intensity oxidative stress and endothelial dysfunction. Background technique [0003] Oxidative stress means the production of free radicals or free radical compounds that cause damage to cells and surrounding tissues (Pathophysiology: the biological basis for disease inadults and children), McCance & Huether 1998, pp. 48-54). [0004] Endothelial dysfunction means those dysfunctions related to the vascular endothelium. As described below (Pathophysiology: The Biological Basis of Disease in Adults and Children, McCance & Huether 1998, p. 1025), damage to the vascular endothelium is k...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07C219/22C07C219/24C07C229/42C07C233/25C07D219/10C07D295/08C07D309/30C07D401/12C07D499/00C07F9/38C07H15/252A61K31/21A61P39/06C07C219/00C07D499/48A61K31/00A61K31/221A61K31/222A61K31/235A61K31/365A61K31/366A61K31/43A61K31/4365A61K31/437A61K31/454A61K31/473A61K31/496A61K31/663A61K31/704A61K38/00A61P1/02A61P3/06A61P3/10A61P7/02A61P9/08A61P9/12A61P11/06A61P11/08A61P11/10A61P11/12A61P19/08A61P25/02A61P25/28A61P29/00A61P31/04A61P31/12A61P35/00A61P37/08A61P43/00C07C69/618C07C69/708C07C203/04C07C219/10C07C219/14C07C219/30C07C229/00C07C233/00C07C317/44C07D213/00C07D219/00C07D295/00C07D295/088C07D307/80C07D309/00C07D333/00C07D401/00C07D471/00C07D471/04C07D495/00C07D495/04C07D499/68C07H15/00
CPCC07C317/44C07F9/3873C07D499/00C07C233/25C07D219/10C07D309/30C07D295/088C07D401/12C07C219/22C07H15/252C07C219/24C07C2102/08C07C203/04C07C229/42C07C2602/08A61P1/02A61P11/06A61P11/08A61P11/10A61P11/12A61P19/08A61P25/02A61P25/28A61P29/00A61P3/10A61P31/04A61P31/12A61P35/00A61P3/06A61P37/08A61P43/00A61P7/02A61P9/08A61P9/12C07D235/28C07D307/84C07D471/04C07D473/18C07D495/04
Inventor P·德尔索尔达托
Owner NICOX SA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap